1. Emerging treatment strategies in recurrent platinum-sensitive ovarian cancer: Focus on trabectedin 
Andrés Poveda, Isabelle Ray-Coquard, Ignacio Romero, Jose Antonio Lopez-Guerrero, Nicoletta Colombo 
Cancer Treatment Reviews 
Volume 40, Issue 3, Pages (April 2014)
DOI: /j.ctrv
Copyright © 2013 The Authors Terms and Conditions

2. Fig. 1 Mechanism of action of trabectedin.
Cancer Treatment Reviews  , DOI: ( /j.ctrv )
Copyright © 2013 The Authors Terms and Conditions

3. Fig. 2
Final analysis of overall survival in all randomized patients and patient subgroups according to platinum-sensitivity according to the Cox regression proportional hazard model. HR and p value for treatment comparison (over PLD alone) based on Cox regression analysis after adjustment for key prognostic factors: ECOG performance status, PFI as a continuous variable, race, baseline CA-125, age, baseline liver/lungs involvement and prior taxane. CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; PFI, platinum-free interval; PLD, pegylated liposomal doxorubicin; OS, overall survival.
Cancer Treatment Reviews  , DOI: ( /j.ctrv )
Copyright © 2013 The Authors Terms and Conditions

4. Fig. 3
Final analysis of overall survival in patients with partially platinum-sensitive disease (PFI of 6–12months) from OVA-301 receiving platinum as first subsequent third-line chemotherapy (unstratified log-rank test according to Kaplan–Meier analysis). C, number of censored patients; CI, confidence interval; PFI, platinum-free interval; HR, hazard ratio; PLD, pegylated liposomal doxorubicin; OS, overall survival; T, trabectedin.
Cancer Treatment Reviews  , DOI: ( /j.ctrv )
Copyright © 2013 The Authors Terms and Conditions